Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00562718 · ClinicalTrials.gov registry record · Phase 2

Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery

A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.

Completed
Registry status
Phase 2
Development phase
50
Enrollment target

NCT00562718: Completed Phase 2 study, sponsored by University of Texas Southwestern Medical Center.

NCT00562718 is a Phase 2 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00562718, a Phase 2 study, has completed, sponsored by University of Texas Southwestern Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
50 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Capecitabine may also make tumor cells more sensitive to radiation therapy. Giving radiation together with capecitabine after surgery may kill any remaining tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving capecitabine together with radiation therapy works in treating patients with nonmetastatic breast cancer.

Primary Outcome

Primarily Grade 1 and 2 toxicities attributable to capecitabine

Interventions

  • DRUG capecitabine
  • RADIATION radiation therapy
  • PROCEDURE adjuvant therapy

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2004-09
Est. Completion 2009-11
Phase Phase 2

What the finished NCT00562718 record still lists

NCT00562718 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 3 interventions - of which capecitabine is the first listed.

NCT00562718 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00562718 about?

NCT00562718 is a clinical study titled "Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery". RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill tumor cells. Capecitabine may also make tumor cells more sensitive t...

What is the current status of trial NCT00562718?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2004-09. Estimated completion is 2009-11.

What interventions are being tested in trial NCT00562718?

The interventions under investigation include: capecitabine (DRUG), radiation therapy (RADIATION), adjuvant therapy (PROCEDURE).

Who is sponsoring clinical trial NCT00562718?

This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00562718's enrollment target sits among peer trials

50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00562718, the US trial registry maintained by the National Library of Medicine. NCT00562718 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.